Last reviewed · How we verify
NCT06836011
A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact.
trial in ATTR Amyloidosis With Cardiomyopathy in 600 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Medical University of Vienna |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 1 January 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2026 |
| Sites | 8 locations across Austria, Netherlands, Germany, Italy |
Conditions studied
- ATTR Amyloidosis With Cardiomyopathy — all drugs for ATTR Amyloidosis With Cardiomyopathy →
- ATTR-CM — all drugs for ATTR-CM →
- ATTR Amyloidosis Wild Type — all drugs for ATTR Amyloidosis Wild Type →
- Mitral Regurgitation — all drugs for Mitral Regurgitation →
Sponsor
Medical University of Vienna
Who can join
18 and older, any sex, with ATTR Amyloidosis With Cardiomyopathy or ATTR-CM. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this prospective registry study is to comprehensively characterize the prevalence, (semi-) quantitative parameters, and associated clinical outcomes of mitral (MR) and tricuspid regurgitation (TR) in patients diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM). The study further aims to develop and implement new grading standards for the quantitative assessment of regurgitation severity, tailored to the distinct hemodynamic profile of ATTR-CM. This approach seeks to address the limitations of current regurgitation severity classifications, which do not adequately reflect the unique pathophysiology of a restrictive phenotype as seen in ATTR-CM.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06836011
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Medical University of Vienna trials
Trials by the same sponsor.
- NCT07473401 — Retinal Oxygen Metabolism in Children With Myopia · not yet recruiting
- NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
- NCT07516990 — Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoper · NA · recruiting
- NCT07496437 — Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? · NA · not yet recruiting
- NCT07290712 — Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06836011 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of Vienna
- Last refreshed: 19 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06836011.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing